Cagrilintide
AM833 · Long-acting amylin analog
Think of it as a hunger-taming sidekick.
Cagrilintide is like a sidekick in the world of hunger management. It mimics a hormone called amylin, which helps your body feel full and satisfied after eating. By slowing down how quickly food leaves your stomach, it helps you feel full longer and keeps those pesky hunger pangs at bay.
This peptide is being explored as a partner with another compound called semaglutide. Together, they work like a dynamic duo to help people lose weight by reducing appetite and making you feel satisfied with less food. Imagine having a tiny, invisible coach reminding your brain that you've had enough to eat, which can be especially helpful if you're trying to manage your weight.
While still under investigation and not yet approved for general use, cagrilintide shows promise in helping with significant weight loss when used in combination with semaglutide.
Who it's for
- People looking to manage their weight more effectively.
- Those who struggle with feeling full after meals.
- Individuals interested in cutting-edge weight management options.
- Biohackers curious about new appetite-regulating peptides.
Probably not for you if…
- Anyone uncomfortable with investigational compounds.
- People seeking a quick fix without lifestyle changes.
- Individuals who prefer tried-and-true methods over new research.
Editorial summary for research context · Not medical advice
Mechanism of Action
Cagrilintide is an investigational long-acting amylin analog engineered for once-weekly dosing. Amylin is co-secreted with insulin by pancreatic beta cells and acts on hypothalamic amylin receptors to slow gastric emptying, suppress glucagon, and reduce food intake. Cagrilintide's extended half-life makes it suitable for weekly administration and it is most advanced as a co-formulated partner with semaglutide (CagriSema), developed by Novo Nordisk. It is investigational and not FDA-approved — only pharmaceutical-grade product under clinical supervision is appropriate for human use.
Researched Benefits
Weight reduction as monotherapy
Phase 2 monotherapy trial reported ~10% weight loss at the 4.5mg weekly dose over 26 weeks.
- [Lau et al. 2021]
Additive effect with GLP-1 agonists
CagriSema (cagrilintide + semaglutide 2.4mg) demonstrated ~15–17% weight loss in Phase 2, with Phase 3 REDEFINE trials reporting ~22% at 68 weeks.
- [Enebo et al. 2021]
- [Garvey et al. 2024 (REDEFINE-1)]
Appetite and satiety modulation
Research suggests complementary mechanism to GLP-1 — amylin signaling targets distinct hindbrain circuits, potentially explaining additive appetite suppression.
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Clinical titration (investigational — prescription required)
- Dosage
- 0.3 mg
- Frequency
- once weekly
- Timing
- same day each week
- Cycle
- 4 weeks
Trials titrate through 0.3, 0.6, 1.2, 2.4, and 4.5mg weekly. No approved formulation — only pharmaceutical-grade product under clinical supervision is appropriate.
Reported Side Effects
- Gastrointestinal: nausea, vomiting, diarrhea (generally milder than GLP-1 class)
- Injection-site reactions
- Decreased appetite and early satiety
- Fatigue reported in some trial participants
Contraindications
- Pregnancy and lactation
- History of pancreatitis
- Severe gastroparesis
Stacking Partners
Peptides commonly paired with Cagrilintide in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Gear + Companions
Reconstitution supplies and research-backed supplement companions for Cagrilintide. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.
Gear you'll need
· Reconstitution + storage essentialsBacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
Stacks well with
· Supplement companions — independent evidence, not sponsoredLMNT Electrolyte Drink Mix Variety Pack (30 sticks)
LMNT
GLP-1 agonism suppresses thirst — dehydration + electrolyte drop is the #1 source of the 'GLP-1 flu' complaint. LMNT targets that gap directly.
Psyllium Husk Fiber Capsules (500 ct)
NOW Foods
Constipation is the most-reported GLP-1 side effect. Daily soluble fiber addresses it without blunting the appetite effect.
Whey Protein Isolate 5 lb (Grass-Fed, Unflavored)
NAKED Nutrition
Appetite suppression tanks protein intake if you don't actively defend it — protein powder is the cheapest floor against lean-mass loss.
As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
16:13I’m a Pathologist. Retatrutide is NOT Ozempic. It’s Biological Overdrive.
Dr. Amin Hedayat, MD
520.2K views · 16:13 · 1 month ago
4:41What happens to your body when you stop taking weight-loss drugs l GMA
Good Morning America
434.8K views · 4:41 · 2 years ago
11:01Dr. Explains Why Retatrutide is KING of Fat Loss Peptides
This Is Not Covered - Dr. Ashley Froese
394.7K views · 11:01 · 2 months ago
12:39Dr. Explains FAT LOSS Peptides That WORK
This Is Not Covered - Dr. Ashley Froese
88.6K views · 12:39 · 3 months ago
10:17Semaglutide: Dosage & Timing Hacks For Maximum Effect
Allure Medical
67.5K views · 10:17 · 1 year ago
Research Papers
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, et al. · The Lancet · 2021
PubMed 34388386 →Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management
Enebo LB, et al. · The Lancet · 2021
PubMed 33894838 →